Skip to main content
Two scientists in lab attire looking through a microscope at a syringe in one of the scientists' hands

Towards an HIV Cure

AIM: To drive concerted efforts to accelerate global scientific research, advocacy and collaboration towards a cure for HIV

It is time to more firmly plant the need for an HIV cure on the policy agenda. While interventions that lead to a meaningful cure are at least decades away, we must begin planning for it sooner than later. Once available, we must ensure a cure can be successfully delivered to those countries most burdened by the disease, and delivery must come at speed.

Sharon Lewin
IAS Towards an HIV Cure Advisory Board Co-Chair

Accelerating global scientific research, advocacy and collaboration towards a cure for HIV is a major strategic priority for the IAS. In 2011, the IAS launched the Towards an HIV Cure programme, which focuses on advancing the HIV cure field in countries where resources for HIV cure research are limited and facilitating interaction with HIV and other biomedical research areas. 

It does so by:

  • Promoting scientific exchange and collaboration and increased research literacy
  • Growing capacity-building programmes for HIV researchers and community advocates in countries where resources for HIV cure research are limited
  • Advocating for the prioritization of HIV cure in the global health agenda by supporting a well-informed, multidisciplinary network

Contact

hivcure@iasociety.org 

With support from:

Related resources

Research Priorities for an HIV Cure: IAS Global Scientific Strategy 2021

Towards an HIV Cure Advisory Board

Towards an HIV Cure Advisory Board

  • Charu Kaushic, Canadian Institute of Health Research (CIHR), Canada

  • Diana Finzi, NIAID/NIH, United States

  • Florence Thune, Sidaction, France

  • Glaudina Loots, Department of Science & Technology, South Africa

  • Glenda Gray, South African Medical Research Council, South Africa

  • Maureen Goodenow, NIH-OAR, United States

  • Remko van Leeuwen, Aidsfonds, The Netherlands

  • Meg Doherty, WHO, Switzerland

  • Michaela Müller-Trutwin, ANRS and Institut Pasteur, France

  • Mike McCune, Bill & Melinda Gates Foundation, United States

  • Mitchell Warren, AVAC, United States

  • Moses Supercharger Nsubuga, Stigmaless, Uganda

  • Peter Godfrey-Faussett, UNAIDS, Switzerland

  • Richard Jefferys, Treatment Action Group (TAG), United States

  • Rowena Johnston, amfAR, United States

  • Sharon Lewin, The Doherty Institute, University of Melbourne, Australia

  • Steve Deeks, UCSF, United States

  • Thumbi Ndung'u, University of KwaZulu-Natal and AHRI, South Africa

  • Yiming Shao, CDC, China

 

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.